A European Medicines Agency committee, on Thursday, accepted the use of an artificial intelligence (AI) tool called AIM-NASH ...
In the early stages, fatty liver may be asymptomatic, with most people unaware they have it. However, continued fat buildup ...
tool called AIM-NASH in clinical trials to help identify the severity of a type of fatty liver disease. The condition, called metabolic dysfunction-associated steatohepatitis, or MASH, is a ...
The doctor explained that beside alcohol consumption and hepatitis, hypertension can contribute significantly to liver fibrosis.
For the first time, the European Medicines Agency has recognized AI software for the diagnosis of fatty liver hepatitis as ...
Non-alcoholic fatty liver disease (NAFLD) represents the most common liver disease worldwide affecting approximatively 20–30% ...
While the myelofibrosis drug landscape has become more crowded since Syntara (then Pharmaxis) decided to focus on that ...